Neuren Pharmaceuticals DAYBUE® Global Net Sales Projected to Reach ~US$700 million by 2028
Neuren Pharmaceuticals Limited (ASX: NEU) has provided key highlights from Acadia Pharmaceuticals' presentation at the 44th annual J.P. Morgan Healthcare Conference. DAYBUE® is projected to reach global net sales of approximately US$700 million by 2028, driven by several key factors: the rollout of the DAYBUE STIX formulation in the US, which will expand the patient base, the continued growth from US customer-facing team expansions in Q2 2025, and international expansion contingent on expected European approval in Q1 2026.
Since its US launch in 2023, more than 2,000 Rett syndrome patients have been treated with DAYBUE, and its 12-month persistency rate has increased to 55%. Acadia is also advancing the DAYBUE STIX formulation, with full US availability anticipated by Q2 2026. Additionally, the DAYBUE oral solution has been approved by Israel’s Ministry of Health, and top-line results from the ongoing Phase 3 trial of trofinetide in Japan are expected between Q4 2026 and Q1 2027.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Neuren Pharmaceuticals DAYBUE® Global Net Sales Projected to Reach ~US$700 million by 2028
Neuren Pharmaceuticals Limited (ASX: NEU) has provided key highlights from Acadia Pharmaceuticals' presentation at the 44th annual J.P. Morgan Healthcare Conference. DAYBUE® is projected to reach global net sales of approximately US$700 million by 2028, driven by several key factors: the rollout of the DAYBUE STIX formulation in the US, which will expand the patient base, the continued growth from US customer-facing team expansions in Q2 2025, and international expansion contingent on expected European approval in Q1 2026.
Since its US launch in 2023, more than 2,000 Rett syndrome patients have been treated with DAYBUE, and its 12-month persistency rate has increased to 55%. Acadia is also advancing the DAYBUE STIX formulation, with full US availability anticipated by Q2 2026. Additionally, the DAYBUE oral solution has been approved by Israel’s Ministry of Health, and top-line results from the ongoing Phase 3 trial of trofinetide in Japan are expected between Q4 2026 and Q1 2027.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au